Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

Starting January 1, the cost of the popular weight loss medication Wegovy will drop significantly in Israel—but only for its ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...

CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

There are several different drugs including tirzepatide (Mounjaro), Ozempic, Saxenda and Wegovy available, and now a new drug, retatrutide – dubbed the “Godzilla” – which claims to be more ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% of their body weight. But the drugs don’t work for everyone.

including the obesity drugs Wegovy and Mounjaro. The use of either prescription — which Dr. Ania Jastreboff tells PEOPLE are "nutrient-stimulated, hormone-based medications" that target the ...

Wegovy, also made by Novo Nordisk and with the same active ingredient as Ozempic, and Eli Lilly's Zepbound, with the same active ingredient as Mounjaro, are FDA-approved for weight loss.

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat ... Could Ozempic and Wegovy come off the shortage list?